The Role of Lectin Pathway Biomarkers in the Development of Diabetic Kidney Disease

Study on the Association between Complement Lectin Pathway-related Markers and the Occurrence and Development of Diabetic Kidney Disease

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500111178

Enrollment

Unknown

Registered

2025-10-27

Start date

2025-07-30

Completion date

Unknown

Last updated

2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Kidney Disease

Interventions

The diabetic group without diabetic kidney disease:none

Diabetic kidney disease stage I-II group:none

Diabetic kidney disease stage ? group:none

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.DM patients who were hospitalized in the Department of Nephrology of the Second Affiliated Hospital of Army Medical University (Xinqiao Hospital) from July 2025 and diagnosed by renal biopsy; 2.All patients whose serum creatinine tests were conducted in our hospital and who maintained regular follow-ups during the treatment period; 3.Patients with complete clinical data and biological sample information, including medical history, physical examination, laboratory tests, imaging examinations and other relevant data; 4.All study participants were aged from 18 to 90 years old; 5.All study participants signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with concurrent various infections, those with acute kidney injury, post - transplantation patients, etc. 2.Patients themselves have factors that can activate serum complement, such as patients with chronic liver diseases, rheumatoid arthritis, and those in the active stage of systemic lupus erythematosus (SLE), etc. 3.Patients with a history of immune system disorders. 4.Patients with other conditions capable of leading to renal lesions.

Design outcomes

Primary

Measure	Time frame
Mannose-Binding Lectin-Associated Serine Protease 2;	—

Secondary

Measure	Time frame
Body Mass Index;Systolic Blood Pressure;Diastolic Blood Pressure;Fasting Blood Glucose;Serum Urea;Serum Uric Acid;Serum Albumin;Hemoglobin;Glycated Hemoglobin;Total Cholesterol;Triglyceride;High-Density Lipoprotein Cholesterol; Low-Density Lipoprotein Cholesterol;Serum Creatinine;Estimated Glomerular Filtration Rate;24-Hour Urinary Protein;Urinary Albumin-to-Creatinine Ratio;Complement C3;Complement C4;Glomerular Lesions;Tubulointerstitial Lesions;Vascular Lesions;Deposition of complement components (C3, C4c, C1q) and immunoglobulins (IgG, IgM) in glomeruli and tubulointerstitium;	—

Measure

Time frame

Body Mass Index;Systolic Blood Pressure;Diastolic Blood Pressure;Fasting Blood Glucose;Serum Urea;Serum Uric Acid;Serum Albumin;Hemoglobin;Glycated Hemoglobin;Total Cholesterol;Triglyceride;High-Density Lipoprotein Cholesterol; Low-Density Lipoprotein Cholesterol;Serum Creatinine;Estimated Glomerular Filtration Rate;24-Hour Urinary Protein;Urinary Albumin-to-Creatinine Ratio;Complement C3;Complement C4;Glomerular Lesions;Tubulointerstitial Lesions;Vascular Lesions;Deposition of complement components (C3, C4c, C1q) and immunoglobulins (IgG, IgM) in glomeruli and tubulointerstitium;

—

Countries

China

Contacts

Public ContactHe Ting

Department of Nephrology, the Second Affiliated Hospital of Army Medical University

tingsr2000@sina.com+86 186 2305 2911

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026